Jade reports interim Phase I results of JADE101 for IgAN
Key findings show mean IgA reductions of around 70% from baseline, sustained at 12 weeks at the 700mg dose.
News
Labcorp announces partnership for colorectal cancer trials
Kalohexis doses first patients in 710GO Phase I trial for obesity
First participant dosed in Jade’s Phase II JUNIPER trial for IgAN
Lilly reports positive interim results from Heart-2 trial of VERVE-102
Caliway secures FDA clearance for CBL-514 clinical trial
First patient dosed in Merck’s Phase III PROCEADE-CRC-03 trial for mCRC
HAYA Therapeutics doses first cohort in Phase I HTX-001 trial
